DAIICHI SANKYO S/ADR (DSNKY)
DSNKY moved a median of -0.03% 30 minutes after news, and +0.09% by the close. How DSNKY actually reacts to news — the realized, point-in-time move the market made, measured across 124 labeled events over the last three years with zero look-ahead.
DSNKY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 43% | 123 |
| 30-min | -0.03% | 46% | 124 |
| 60-min | +0.07% | 54% | 124 |
| to close | +0.09% | 52% | 124 |
| Middle 50% of DSNKY reactions | -0.62% to +0.77% |
|---|---|
| Median reaction (30-min) | -0.03% |
| Measured reactions | 124 |
Half of all DAIICHI SANKYO S/ADR news events land between -0.62% and +0.77% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when DSNKY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to DSNKY's baseline. Nothing else.
Recent DSNKY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn | Press release | Business Wire | +0.06% | +0.89% | |
| Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer | Press release | Business Wire | +0.00% | +2.77% | |
| Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial | Press release | Business Wire | +0.00% | +0.00% | |
| Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer | Press release | Business Wire | +0.00% | +0.11% | |
| New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk | Press release | Business Wire | -1.74% | -1.71% | |
| DS1025 Enters Clinical Development in Patients with Advanced Solid Tumors as Novel CD25 Directed ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo | Press release | Business Wire | +0.00% | +0.22% | |
| TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer | Press release | Business Wire | -0.08% | -1.33% | |
| Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio | Press release | Business Wire | -1.43% | -1.26% | |
| Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization | Press release | Business Wire | -1.43% | -1.26% | |
| Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial | Press release | Business Wire | +4.01% | +4.42% | |
| Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results | Press release | Business Wire | +6.66% | +4.33% | |
| Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy | Press release | Business Wire | +6.66% | +4.33% | |
| Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer | Press release | Business Wire | -0.09% | -1.15% | |
| Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors | Press release | Business Wire | +0.40% | -0.28% | |
| Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy | Press release | Business Wire | +0.48% | +1.28% | |
| Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO | Press release | Business Wire | +4.05% | +5.30% | |
| Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 2026 | Press release | Business Wire | -0.01% | -0.03% | |
| Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates | Press release | Business Wire | +2.86% | +3.23% | |
| Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors | Press release | Business Wire | +2.86% | +3.23% | |
| Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer | Press release | Business Wire | -0.28% | -2.17% | |
| Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation | Press release | Business Wire | -2.44% | -1.16% | |
| Interna Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance MNM-Based Targeted Delivery Technologies | Press release | PR Newswire | -0.88% | -0.27% | |
| Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase | Press release | PR Newswire | +1.22% | +0.49% | |
| Tempus Announces Strategic Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Clinical Differentiation Across an ADC Clinical Program | Press release | Business Wire | +0.00% | +2.47% | |
| ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer | Press release | Business Wire | +0.95% | +2.87% | |
| GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe. | Press release | Business Wire | -0.65% | -0.99% | |
| Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D | Press release | Business Wire | +0.00% | +1.18% | |
| ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer | Press release | Business Wire | -1.26% | -0.74% | |
| DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo | Press release | Business Wire | +5.50% | +4.71% | |
| DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy | Press release | Business Wire | -2.78% | -1.52% | |
| Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe | Press release | Business Wire | +0.91% | +1.37% | |
| Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology | Press release | Canada Newswire | +0.26% | +0.40% | |
| ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer | Press release | Business Wire | -2.42% | -1.49% | |
| TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer | Press release | Business Wire | +0.00% | -2.83% | |
| Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe | Press release | Business Wire | +0.00% | +0.66% | |
| DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer | Press release | Business Wire | +2.39% | +2.15% | |
| ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer | Press release | Business Wire | +2.39% | +2.15% | |
| DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy | Press release | Business Wire | -0.23% | -0.65% | |
| ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer | Press release | Business Wire | -0.09% | +0.18% | |
| Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research | Press release | PR Newswire | +3.40% | +4.97% | |
| DESTINY-Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer | Press release | Business Wire | +0.38% | +1.58% | |
| Daiichi Sankyo Showcases Strength of Industry-Leading ADC Portfolio with Latest Research Updates from Five Landmark Breast Cancer Trials at SABCS | Press release | Business Wire | -1.84% | -1.34% | |
| Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen | Press release | Business Wire | +1.62% | +2.70% | |
| Allegro and American Regent sign exclusive licensing deal for SynoglideTM, a novel osteoarthritis treatment in animal health, valued at up to $35 million | Press release | GlobeNewswire | +2.51% | +3.18% | |
| General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutics Using OmniTAC™ Platform | Press release | PR Newswire | +0.02% | -0.02% | |
| DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo | Press release | Business Wire | -2.75% | -3.46% | |
| DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer | Press release | Business Wire | -2.71% | -3.60% | |
| DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02 | Press release | Business Wire | +0.00% | -0.09% | |
| DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial | Press release | Business Wire | +0.00% | -0.09% | |
| ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial | Press release | Business Wire | +0.00% | -0.09% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the DSNKY section they belong to.
Where else DSNKY is measured.
DSNKY earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| BIOTRICITY INC (BTCY) | 124 | 0.00% | 38% |
| CLEMENTIA PHARMACEUTICALS INC COMMON SHARES (CMTA) | 124 | +0.03% | 51% |
| LIANLUO SMART LTD COMMON (LLIT) | 123 | -0.98% | 28% |
| Medite Cancer Diagnostics, Inc. (MDIT) | 123 | 0.00% | 2% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is DAIICHI SANKYO S/ADR's median reaction calculated?
Every labeled DSNKY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 124 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of DSNKY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does DSNKY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.